Swedish prices for medicines among the lowest in Europe

11 December 2019 - Since 2014, the Dental and Pharmaceutical Benefits Agency, TLV, has conducted an annual international price comparison ...

Read more →

Agneta Karlsson new Director General at TLV

28 November 2019 - Today the Government has appointed Agneta Karlsson as new Director General of the Authority Dental Care and ...

Read more →

Zejula is included in the high-cost protection with limitation

25 November 2019 - Zejula (niraparib) is included in the high-cost, limited-subsidy protection from December 1, 2019.  ...

Read more →

Withdrawal from the drug benefits on 1 December

15 November 2019 - Below is a compilation of the medicines in different packaging sizes which, at the companies' own ...

Read more →

Health economic assessment of Tecentriq for triple negative breast cancer

8 November 2019 - TLV has produced a health economic knowledge base for the county council for the drug Tecentriq (atezolizumab).  ...

Read more →

Parallel distributed or parallel imported Maviret and Viekirax remain in high cost protection

28 October 2019 - TLV has reconsidered the subsidy for parallel distributed or parallel imported Maviret and Viekirax and decided ...

Read more →

The district court rejected an appeal against Darzalex

21 October 2019 - TLV's decision to reject the grant application for Darzalex was appealed to the Administrative Court in ...

Read more →

Withdrawals from the drug benefits - August 2019

8 July 2019 - Etalpha 80 mg & 100 capsules, Leflunomide medac 15 mg & 30 tablets and Maviret 100 mg ...

Read more →

Gefitinib in new exchange group

28 June 2019 - As of June, gefitinib is included as an exchange group on the list of period goods. ...

Read more →

Joint evaluation report of sotagliflozin (Zynquista)

28 June 2019 - TLV, together with the corresponding authorities in the Netherlands, ZIN, and in Ireland, NCPE, have written ...

Read more →

Health economic assessment of Kymriah in diffuse large B-cell lymphoma

20 June 2019 - TLV has produced a health economic knowledge base for county councils for CAR-T cell treatment Kymriah ...

Read more →

TLV does not extend Hemlibra's current subsidy

18 June 2019 - Hemlibra has been included in the high-cost protection since autumn 2018 for the treatment of patients ...

Read more →

Review of Rotarix

12 June 2019 - TLV has decided to initiate a review of the drug Rotarix due to the Government's decision ...

Read more →

TLV publishes first joint report within the FINOSE co-operation

11 June 2019 - FINOSE is a collaboration between the HTA authorities, the pharmaceutical company Fimea (Finland), the Norwegian Medicines Agency, ...

Read more →

Health economic assessment of Luxturna in the treatment of visual impairment caused by hereditary eye disease

29 May 2019 - TLV has produced a health economic knowledge base for the region for the drug Luxturna (voretigene ...

Read more →